Registry of Asian patients with myeloproliferative neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort registry collects data on patients diagnosed with myeloproliferative neoplasms (MPN) across multiple centers in Asia. It includes both prospective and retrospective data collection, focusing on clinicopathologic, cytogenetic, and mutational characteristics, as well as treatment responses and outcomes. Patients diagnosed between 2010 and 2025 will be monitored through routine clinic visits and medical record reviews, with data collected at diagnosis and approximately every six months thereafter. The aim is to establish a comprehensive clinical registry to better understand MPN in the Asian population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old at the time of diagnosis of MPN.
2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):

   1. Polycythaemia vera
   2. Essential thrombocythemia
   3. Primary myelofibrosis, pre-fibrotic/early stage
   4. Primary myelofibrosis, overt fibrotic stage
   5. Post-polycythaemia vera myelofibrosis
   6. Post-essential thrombocythaemia myelofibrosis
   7. MPN-unclassifiable
3. All subjects need to provide informed consent.

Exclusion Criteria:

A subject will not be eligible if he/she meets any of the following criteria:

1\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification

Where it's running

• Department of Medicine, Queen Mary Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Harinder Gill, MD — The University of Hong Kong
• Study coordinator: Harinder Gill, MD
• Email: gillhsh@hku.hk
• Phone: +852 22554542

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Combining Pacritinib and Talazoparib for Patients with Myeloproliferative Neoplasms Not Responding to JAK2 Therapy

  This study is testing a combination of two medications, pacritinib and talazoparib, to see if they can help patients with certain blood cancers who haven't responded to other treatments.

  Recruiting Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06218628

• Evaluating CALR Allele Burden in Myeloproliferative Neoplasms

  This study is trying to see if tracking a specific genetic change in the blood can help doctors understand how myeloproliferative neoplasms progress in patients over time.

  Recruiting at 10 sites University Hospital, Angers · Angers and 9 other locations · NCT04942080

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.